🚀 VC round data is live in beta, check it out!
Johnson & Johnson Valuation Multiples
Discover revenue and EBITDA valuation multiples for Johnson & Johnson and similar public comparables like AbbVie, Roche, AstraZeneca, Eli Lilly and more.
Johnson & Johnson Overview
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Founded
1887
HQ
Employees
138.2K
Website
Financials (LTM)
EV
$583B
Johnson & Johnson Financials
Johnson & Johnson reported last 12-month revenue of $96B and EBITDA of $36B.
In the same LTM period, Johnson & Johnson generated $69B in gross profit, $36B in EBITDA, and $27B in net income.
Revenue (LTM)
Johnson & Johnson P&L
In the most recent fiscal year, Johnson & Johnson reported revenue of $94B and EBITDA of $41B.
Johnson & Johnson expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $96B | XXX | $94B | XXX | XXX | XXX |
| Gross Profit | $69B | XXX | $64B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $36B | XXX | $41B | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 44% | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $27B | XXX | $27B | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | — | — | $28B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Johnson & Johnson Stock Performance
Johnson & Johnson has current market cap of $556B, and enterprise value of $583B.
Market Cap Evolution
Johnson & Johnson's stock price is $230.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $583B | $556B | -1.5% | XXX | XXX | XXX | $11.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJohnson & Johnson Valuation Multiples
Johnson & Johnson trades at 6.1x EV/Revenue multiple, and 16.3x EV/EBITDA.
EV / Revenue (LTM)
Johnson & Johnson Financial Valuation Multiples
As of April 22, 2026, Johnson & Johnson has market cap of $556B and EV of $583B.
Equity research analysts estimate Johnson & Johnson's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Johnson & Johnson has a P/E ratio of 20.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $556B | XXX | $556B | XXX | XXX | XXX |
| EV (current) | $583B | XXX | $583B | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 14.2x | XXX | XXX | XXX |
| EV/EBIT | 18.6x | XXX | 19.2x | XXX | XXX | XXX |
| EV/Gross Profit | 8.5x | XXX | 9.1x | XXX | XXX | XXX |
| P/E | 20.7x | XXX | 20.7x | XXX | XXX | XXX |
| EV/FCF | 25.7x | XXX | 27.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Johnson & Johnson Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Johnson & Johnson Margins & Growth Rates
Johnson & Johnson's revenue in the last 12 month grew by 7%.
Johnson & Johnson's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Johnson & Johnson's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Johnson & Johnson's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Johnson & Johnson Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Johnson & Johnson Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca | XXX | XXX | XXX | XXX | XXX | XXX |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Merck | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Johnson & Johnson M&A Activity
Johnson & Johnson acquired XXX companies to date.
Last acquisition by Johnson & Johnson was on XXXXXXXX, XXXXX. Johnson & Johnson acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Johnson & Johnson
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJohnson & Johnson Investment Activity
Johnson & Johnson invested in XXX companies to date.
Johnson & Johnson made its latest investment on XXXXXXXX, XXXXX. Johnson & Johnson invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Johnson & Johnson
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Johnson & Johnson
| When was Johnson & Johnson founded? | Johnson & Johnson was founded in 1887. |
| Where is Johnson & Johnson headquartered? | Johnson & Johnson is headquartered in United States. |
| How many employees does Johnson & Johnson have? | As of today, Johnson & Johnson has over 138K employees. |
| Who is the CEO of Johnson & Johnson? | Johnson & Johnson's CEO is Joaquin Duato. |
| Is Johnson & Johnson publicly listed? | Yes, Johnson & Johnson is a public company listed on NYSE. |
| What is the stock symbol of Johnson & Johnson? | Johnson & Johnson trades under JNJ ticker. |
| When did Johnson & Johnson go public? | Johnson & Johnson went public in 1944. |
| Who are competitors of Johnson & Johnson? | Johnson & Johnson main competitors are AbbVie, Roche, AstraZeneca, Eli Lilly. |
| What is the current market cap of Johnson & Johnson? | Johnson & Johnson's current market cap is $556B. |
| What is the current revenue of Johnson & Johnson? | Johnson & Johnson's last 12 months revenue is $96B. |
| What is the current revenue growth of Johnson & Johnson? | Johnson & Johnson revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Johnson & Johnson? | Current revenue multiple of Johnson & Johnson is 6.1x. |
| Is Johnson & Johnson profitable? | Yes, Johnson & Johnson is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Johnson & Johnson? | Johnson & Johnson's last 12 months EBITDA is $36B. |
| What is Johnson & Johnson's EBITDA margin? | Johnson & Johnson's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Johnson & Johnson? | Current EBITDA multiple of Johnson & Johnson is 16.3x. |
| What is the current FCF of Johnson & Johnson? | Johnson & Johnson's last 12 months FCF is $23B. |
| What is Johnson & Johnson's FCF margin? | Johnson & Johnson's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Johnson & Johnson? | Current FCF multiple of Johnson & Johnson is 25.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.